The following is a summary of “FcγR3A polymorphism influences natural killer cell activation and response to anti-PD-L1 (avelumab) in gestational trophoblastic neoplasia,” published in the April 2025 ...

The median disease-free survival (DFS) was not reached (15). Likewise, avelumab was assessed with NACT in a randomized phase II trial where patients were separated into two groups and randomized to ...

According to estimates, among the currently marketed drugs, BAVENCIO (avelumab) as first-line therapy held the largest market share, generating approximately USD 290 million in revenue across the ...

VXM01, an investigational, oral, anti-VEGFR vaccine, was found safe and showed early signs of efficacy with avelumab (Bavencio) for recurrent glioblastoma (GBM) in final findings from phase 2a ...

According to the study design, no regular maintenance treatment with avelumab was planned in the comparator arm for patients who were progression-free following chemotherapy. However, maintenance ...

Treatment with Bavencio (avelumab) as first-line maintenance was associated with long-term efficacy and consistent safety in patients with advanced urothelial carcinoma regardless of if they had ...

According to the study design, no regular maintenance treatment with avelumab was planned in the comparator arm for patients who were progression-free following chemotherapy. However, maintenance ...

According to the study design, no regular maintenance treatment with avelumab was planned in the comparator arm for patients who were progression-free following chemotherapy. However, maintenance ...

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Among patients with recurrent glioblastoma (GBM), the combination of VXM01, an investigational oral anti–VEGFR-2 vaccine, and the PD-L1 inhibitor avelumab (Bavencio) was generally well tolerated, with ...

"The completion of this Phase 2a study is a significant milestone for Vaximm AG, as it provides strong evidence that VXM01, in combination with avelumab is generally well-tolerated in patients with ...